Alyssum Therapeutics
Pioneering B cell immunotherapy to regulate immune response and treat complex diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
* | $2.0m Valuation: $72.5m | Series A | |
| Total Funding | 000k | ||
Related Content
Alyssum Therapeutics is at the forefront of cancer immunology, focusing on pioneering B cell immunotherapy to regulate immune responses and treat complex diseases. The company operates in the biopharmaceutical sector, targeting complex diseases with a particular emphasis on cancer. Alyssum's business model revolves around developing next-generation targeted immunotherapies, with a strong focus on advancing patient outcomes and quality of life. The company generates revenue through the development and potential commercialization of its therapeutic candidates, such as AT 1965, which is currently under clinical trials. Alyssum serves patients with complex diseases, particularly those with hard-to-treat tumors, and actively recruits participants for its clinical trials. The team at Alyssum boasts extensive experience, having been involved with over 20 drugs on the market and multiple recent accelerated USFDA approvals. The company leverages its expertise to push the boundaries of science, aiming to transform patient lives through innovative treatments.
Keywords: B cell, immunotherapy, cancer, biopharmaceutical, clinical trials, patient outcomes, targeted therapies, immune response, drug development, USFDA approvals.